To include your compound in the COVID-19 Resource Center, submit it here.

NICE draft guidance recommends against Biogen's Spinraza for SMA

U.K.’s NICE published draft guidance recommending against the use of Spinraza nusinersen from Biogen Inc. (NASDAQ:BIIB) to treat spinal muscular atrophy. The committee cited significant uncertainties around Spinraza's long-term benefits, as well as the drug's “extremely high” cost.

Based on Spinraza's

Read the full 408 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers